Catumaxomab
From Wikipedia, the free encyclopedia
|
Catumaxomab?
|
|
| Therapeutic monoclonal antibody | |
| Source | Rat-murine hybrid |
| Target | EpCAM CD3 |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Catumaxomab (removab) is a rat-murine hybrid monoclonal antibody which is used to treat some cancers such as platinum-refractory ovarian cancer, malignant ascites, and gastric cancer. It binds to antigen CD3 and is also trifunctional. It is in clinical trials in the United States currently and is used in Europe.
It works by linking T-lymphocytes with the cancer cells.
|
|||||
 |
This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. |
